ICML 2023 | Harnessing BTKi therapy by CDK4/6i control of T-cell surveillance

Selina Chen-Kiang, PhD, Weill Cornell Medicine, New York City, NY, discusses recent studies investigating palbociclib, a CDK4/6 inhibitor, plus ibrutinib in the treatment of mantle cell lymphoma (MCL; NCT02159755 and NCT03478514). Inhibition of CDK4/6 arrests the cell cycle of MCL cells during the G1 phase, making the cells more vulnerable, and has also been shown to control immune cells. Prof. Chen-Kiang shares the findings of the study, highlighting the achievement of durable complete remission in patients. Prof. Chen-Kiang also comments on the benefits of longitudinal single cell analysis, which can allow the identification of driver alterations throughout therapy and the determination of resistance mechanisms. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.